Study in The Lancet successfully demonstrated endpoints of identifying both vulnerable patients & plaques at a significantly higher risk for subsequent MACE. View now View Now
Together, we are fighting
Coronary Artery Disease
because the heart is everything.
WATCH VIDEO
Now FDA indicated to identify plaque and patients at increased risk of MACE.
Achieve unparalleled insights with the Makoto™ Imaging System and its accompanying Dualpro™ IVUS + NIRS catheter, the only FDA-cleared dual-modality catheter and imaging system indicated for the identification of patients and plaques at increased risk of major adverse cardiac events (MACE).
Don’t waste an opportunity of being inside the patient’s vessel
Bring the Makoto Intravascular Imaging System to your institution today and gain unparalleled insights about your patient’s vessel health.
SIGN UP NOW
Global Products
In 2015, Nipro Corporation acquired lnfraredx, a U.S. Imaging Company, as part of its long-term strategic plan to build a world class cardiovascular brand.
LEARN MORE ABOUT NIPRO
The OKAY II is not yet available for sale in the United States
LRP: Assessment of Coronary Near-Infrared Spectroscopy Imaging to Detect Vulnerable Plaques and Vulnerable Patients
© 2019 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative